Zobrazeno 1 - 10 of 33 pro vyhledávání: '"L. de Prijck"'
1
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)
Autor: O. Koriakine, P.H.M. de Mulder, G. Kaiser, Alan Horwich, B. Paluchowska, A. van Oosterom, Sophie D. Fosså, R. de Wit, Laurence Collette, L. de Prijck
Publikováno v: British Journal of Cancer
British Journal of Cancer, 93(11), 1209-1214. Nature Publishing Group
British Journal of Cancer, 93, 1209-14
British Journal of Cancer, 93, 11, pp. 1209-14
Item does not contain fulltext New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in interme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a005bc4cda5285f6138b93a09335af23
https://doi.org/10.1038/sj.bjc.6602830
Zobrazit plný text záznamu
2
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
Autor: Gerald H. Mickisch, H. Van Poppel, Richard Sylvester, L. de Prijck, A Garin
Publikováno v: Lancet (UK), 358, 966-970. Elsevier Ltd.
Summary Background Surgery is the main treatment for localised renal cell carcinoma, but use of radical nephrectomy for metastatic disease is highly controversial. We aimed to establish whether radical nephrectomy done before interferon-alfa-based im
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f72f3313527d7c3793277727285bef
https://doi.org/10.1016/s0140-6736(01)06103-7
Zobrazit plný text záznamu
3
Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881
Autor: H. Van Poppel, Didier Jacqmin, Richard Sylvester, Fritz H. Schröder, J.H.M. Blom, J.M. Marechal, L. de Prijck
Publikováno v: European Urology, 36(6), 570-575. Elsevier
Objective: The authors present demographic and surgical data from a randomized phase III trial, instituted by the EORTC Genitourinary Group in 1988, the aim of which was to assess w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b32a07f13cf64e282a9f03bc9bfb24c
https://doi.org/10.1159/000020050
Zobrazit plný text záznamu
4
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study
Autor: E. Lallemand, L. Collette, Stan B. Kaye, C.J. van Groeningen, István Bodrogi, S. P. Stenning, L. de Prijck, Sophie D. Fosså, Graham M. Mead, Phm deMulder, R deWit, Richard Sylvester, Michael Cullen
Publikováno v: Journal of Clinical Oncology, 16, 692-701
Journal of Clinical Oncology, 16, 2, pp. 692-701
Journal of Clinical Oncology, 16(2), 692-701. American Society of Clinical Oncology
PURPOSE The aim of this randomized trial was to assess the potential therapeutic advantage of an intensive induction-sequential chemotherapy schedule (bleomycin, vincristine, cisplatin [BOP])/etoposide, ifosfamide, cisplatin, and bleomycin [VIP-B]),
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::331223dd20d6ef46c0a9afb8fd09818a
https://doi.org/10.1200/jco.1998.16.2.692
Zobrazit plný text záznamu
5
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group
Autor: L. de Prijck, S. Horenblas, Sophie D. Fossa, N. Aaronson, R. R. Hall, L. Collette, M. Brausi, P. H.Th. Slee, J. W. Hetherington
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(1)
PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were compared in patients with hormone-resistant prostate cancer (HRPC) treated with prednisone (5 mg orally, four times a day) or flutamide (250 mg orally, three times a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72eb17d42454af73c0717e739ad5a9c9
https://pubmed.ncbi.nlm.nih.gov/11134196
Zobrazit plný text záznamu
6
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group
Autor: J H, Blom, H, van Poppel, J M, Marechal, D, Jacqmin, R, Sylvester, F H, Schröder, L, de Prijck
Publikováno v: European urology. 36(6)
The authors present demographic and surgical data from a randomized phase III trial, instituted by the EORTC Genitourinary Group in 1988, the aim of which was to assess whether complete lymph node dissection in conjunction with radical nephrectomy fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0b4571dee3b182f98f51110bcee8a2f9
https://pubmed.ncbi.nlm.nih.gov/10559610
Zobrazit plný text záznamu
7
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
Autor: L. de Prijck, J.P. Neijt, Richard Sylvester, Dt Sleijfer, W.W. ten Bokkel Huinink, Laurence Collette, Gerrit Stoter, R. de Wit
Publikováno v: British Jounal of Cancer, 78(6), 828-832. Nature Publishing Group
British Journal of Cancer, 76(6), 828-832. Nature Publishing Group
We investigated the efficacy and toxicity of induction chemotherapy with cisplatin and etoposide with either bleomycin or ifosfamide in patients with intermediate-prognosis testicular non-seminoma. A total of 84 eligible patients were randomized to r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c41eea8e167d10a6f01a3ad61530aba
https://research.rug.nl/en/publications/d5d86918-73c1-46c9-b3d0-95025824552c
Zobrazit plný text záznamu
8
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom
Autor: L. de Prijck, S.B. Kaye, I. Bodrogi, C.J. van Groeningen, E. Lallemand, L. Collette, R de Wit, G.M. Mead, M.H. Cullen, SP Stenning, P.H.M. de Mulder, Sophie D. Fosså
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(2)
PURPOSE To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with metastatic poor-prognosis malignant germ cell tumors who receive full dose-intensity combination chemotherapy. PATIENTS AND ME
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da6cd3914244fea752d127248a07528a
https://pubmed.ncbi.nlm.nih.gov/9469362
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje